Sai Life Sciences' Q3 FY 2025-26 Quarterly Results
- 06 Feb 2026
Result Summary
- Sai Life Sciences Ltd reported a 2.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 25.8%.
- Its expenses for the quarter were down by 4.2% QoQ and up 12.0% YoY.
- The net profit increased 19.7% QoQ and increased 86.4% YoY.
- The earnings per share (EPS) of Sai Life Sciences Ltd stood at 4.71 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 564.84 | 552.80 | 448.89 | 2.2% | 25.8% |
Total Expenses | 422.39 | 440.74 | 377.24 | -4.2% | 12.0% |
Profit Before Tax | 134.17 | 112.05 | 71.65 | 19.7% | 87.3% |
Tax | 33.79 | 28.21 | 17.80 | 19.8% | 89.8% |
Profit After Tax | 100.38 | 83.84 | 53.85 | 19.7% | 86.4% |
Earnings Per Share | 4.71 | 3.93 | 2.84 | 19.8% | 65.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sai Life Sciences Ltd is an Indian company primarily engaged in the pharmaceutical industry. It offers contract research, development, and manufacturing services to various pharmaceutical companies globally. The company is known for its capabilities in drug discovery, development, and manufacturing, providing end-to-end integrated services. Although specific recent developments are not available in the provided data, the company operates in a dynamic sector where innovation and regulatory developments play significant roles. Sai Life Sciences Ltd is committed to maintaining high-quality standards, offering customized solutions to meet the diverse needs of its clients.
Revenue
The total income for Sai Life Sciences Ltd in Q3FY26 was ₹564.84 crores, representing a quarter-over-quarter (QoQ) increase of 2.2% from ₹552.80 crores in Q2FY26. On a year-over-year (YoY) basis, the company experienced a significant revenue growth of 25.8% from ₹448.89 crores in Q3FY25. This growth trend showcases a continuous increase in revenue streams, reflecting the company's ability to expand its business operations and capture a larger market share over the past year. The consistent rise in total income highlights the company's operational efficiency and potentially increased demand for its services.
Profitability
Sai Life Sciences Ltd reported a profit before tax of ₹134.17 crores in Q3FY26, marking a 19.7% QoQ increase from ₹112.05 crores in Q2FY26 and an 87.3% YoY increase from ₹71.65 crores in Q3FY25. The profit after tax for Q3FY26 stood at ₹100.38 crores, representing a 19.7% QoQ increase from ₹83.84 crores in Q2FY26 and an 86.4% YoY increase from ₹53.85 crores in Q3FY25. The company also reported earnings per share (EPS) of ₹4.71 in Q3FY26, up 19.8% QoQ from ₹3.93 and 65.8% YoY from ₹2.84 in Q3FY25. This increase in profitability metrics indicates effective cost management and strong revenue performance.
Operating Metrics
Total expenses for Sai Life Sciences Ltd decreased by 4.2% QoQ to ₹422.39 crores in Q3FY26 from ₹440.74 crores in Q2FY26. On a YoY basis, the total expenses rose by 12.0% from ₹377.24 crores in Q3FY25. The tax expense for Q3FY26 was ₹33.79 crores, reflecting a 19.8% QoQ increase from ₹28.21 crores in Q2FY26 and an 89.8% YoY increase from ₹17.80 crores in Q3FY25. These trends in operating metrics indicate a reduction in quarterly expenses while maintaining growth in annual expenses, which may be aligned with strategic investments or expansion. The increase in tax expense correlates with the enhanced profitability of the company, impacting the net earnings positively.